Know Cancer

or
forgot password

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent


N/A
N/A
N/A
Not Enrolling
Male
Prostate Cancer, Osteoporosis

Thank you

Trial Information

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent


Inclusion Criteria:



- pathologic confirmation of prostate cancer

- patients who are taking LHRH antagonist or anti- androgen or both of them within 6
months since starting.

Exclusion Criteria:

- patients who are hard to be analysed by limitation of chart record according to
investigators'discretion

- patients who already have been registered in this study

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Retrospective

Outcome Measure:

To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.

Principal Investigator

Joon Woo Bahn, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca Korea

Authority:

Korea: Food and Drug Administration

Study ID:

NIS-OKR-CAS-2009/1

NCT ID:

NCT01025479

Start Date:

November 2009

Completion Date:

March 2010

Related Keywords:

  • Prostate Cancer
  • Osteoporosis
  • Osteoporosis
  • Prostate cancer
  • LHRH agonist and/or anti-androgen agent
  • Korean prostate cancer
  • Osteoporosis
  • Prostatic Neoplasms

Name

Location